This highly interactive live broadcast will feature leading experts who will address the complex interrelationship of further reducing ASCVD event risk with adjunctive therapies to statin use. This activity will provide the opportunity for the multispecialty faculty and participants to work through complex issues that challenge healthcare providers in caring for patients with elevated atherogenic cholesterol, triglycerides, and diabetes, many of whom have been suboptimally managed and continue to be at risk of advancing cardiovascular disease.
New Data, New Directions in Managing Patients with or at High Risk of ASCVD
Live
Broadcast
Information
October 17, 2020
12:45 PM - 01:45 PM CDT
Online
Share this program on:
Choose a format
Details
Presenters
Comments
Learning Objectives
At the conclusion of this activity, learners should be better able to:
- Discuss recent cardiovascular outcomes trial results and their clinical implications in reducing ASCVD events
- Assess the clinical utility of statin-adjunct therapies for ASCVD event reduction
- Apply recent randomized clinical trial and evidence-based guidelines to reduce ASCVD risk
Target Audience
This activity is designed to meet the educational needs of advanced-level clinicians, including cardiologists, internists, family practice physicians, lipidologists, and allied healthcare professionals. This audience is responsible for the prevention, diagnosis, and management of lipid disorders and cardiometabolic risk.
Accreditation and Credit Designation Statements
The AOA Bureau of OMED is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians.
The AOA Bureau of OMED designates this live program activity for a maximum of 1.00 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
Commercial Support
This activity is supported by an independent educational grant from Amarin Pharma, Inc.
Details
Presenters
Comments
Overview
This highly interactive live broadcast will feature leading experts who will address the complex interrelationship of further reducing ASCVD event risk with adjunctive therapies to statin use. This activity will provide the opportunity for the multispecialty faculty and participants to work through complex issues that challenge healthcare providers in caring for patients with elevated atherogenic cholesterol, triglycerides, and diabetes, many of whom have been suboptimally managed and continue to be at risk of advancing cardiovascular disease.
Learning Objectives
At the conclusion of this activity, learners should be better able to:
- Discuss recent cardiovascular outcomes trial results and their clinical implications in reducing ASCVD events
- Assess the clinical utility of statin-adjunct therapies for ASCVD event reduction
- Apply recent randomized clinical trial and evidence-based guidelines to reduce ASCVD risk
Target Audience
This activity is designed to meet the educational needs of advanced-level clinicians, including cardiologists, internists, family practice physicians, lipidologists, and allied healthcare professionals. This audience is responsible for the prevention, diagnosis, and management of lipid disorders and cardiometabolic risk.
Accreditation and Credit Designation Statements
The AOA Bureau of OMED is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians.
The AOA Bureau of OMED designates this live program activity for a maximum of 1.00 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
Commercial Support
This activity is supported by an independent educational grant from Amarin Pharma, Inc.
Facebook Comments